Bridge Therapeutics
Birmingham, US · Founded 2016 · Delaware corporation
Bridge Therapeutics is a development-stage pharmaceutical company developing BT-219 (Bunalz), a buprenorphine/naloxone orally disintegrating tablet for Opioid Use Disorder, and BT-205, a buprenorphine/meloxicam sublingual combination for chronic pain in opioid-experienced patients. Both drug candidates are being pursued through the FDA 505(B)(2) approval pathway.
BiotechHealthtech
Founders & leadership
GS
Greg SullivanDr.
JM
Joseph MullinNamed on SEC filing
DH
David H BergstromNamed on SEC filing
EK
Elizabeth KelleyNamed on SEC filing
TP
Tim PearaPresident
JG
James G SullivanNamed on SEC filing
DH
Diana HarshbargerNamed on SEC filing
KS
Kelley S AltonNamed on SEC filing
Reported raises · per SEC filings
Form D private placements$2.3M disclosed across 2 rounds · 2019–2023
▶$321KraisedDec 2023 · 22 investors · PharmaceuticalsRule 506(c)
▶$321KraisedDec 2023 · 22 investors · Pharmaceuticals
Rule 506(c)Officers, directors & promoters on the filing
- Christopher PalutisDirector
- Joseph Patrick MullinDirector
- Elizabeth KelleyDirector
- Jason BaileyDirector
- Timothy Grant PearaExecutive Officer
- James Gregory SullivanExecutive Officer, Director
- Offering amount
- $1.5M
- Amount sold
- $321K
- Minimum investment
- $2K
- First sale
- Oct 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06c
▶$2MraisedApr 2019 · 11 investors · PharmaceuticalsRule 506(c)
▶$2MraisedApr 2019 · 11 investors · Pharmaceuticals
Rule 506(c)Officers, directors & promoters on the filing
- Joseph MullinDirector
- David H BergstromDirector
- Elizabeth KelleyDirector
- Tim PearaExecutive Officer
- James G SullivanExecutive Officer, Director
- Russell KelleyPromoter
- Diana HarshbargerDirector
- Kelley S AltonExecutive Officer, Director
- Amount sold
- $2M
- Minimum investment
- $25K
- Sales commissions
- $20K
- Placement agents
- Emerson Equity LLC
- First sale
- Apr 2019
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06c
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlap
Bicycle Health10 shared keywordsBicycle Health provides treatment and support for opioid use disorder (OUD). The company specializes in addressing substance use disorders through clinical care programs.
CBS News9 shared keywordsCBS News is a news organization publishing reporting and video coverage on U.S. and world politics, business, science, health, and entertainment, including its free CBS News 24/7 streaming service.
Companies competing with Bridge Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Bridge Therapeutics do?
- Bridge Therapeutics is a development-stage pharmaceutical company developing BT-219 (Bunalz), a buprenorphine/naloxone orally disintegrating tablet for Opioid Use Disorder, and BT-205, a buprenorphine/meloxicam sublingual combination for chronic pain in opioid-experienced patients. Both drug candidates are being pursued through the FDA 505(B)(2) approval pathway.
- How much funding has Bridge Therapeutics raised?
- Bridge Therapeutics has disclosed $2.3M raised across 2 rounds.
- Where is Bridge Therapeutics headquartered?
- Bridge Therapeutics is headquartered in Birmingham, US.